At 8.4% CAGR, the Europe Home Infusion Therapy Market is projected to be worth US$ 7,281.99 Million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe home infusion therapy market was valued at US$ 4,482.33 million in 2022 and is expected to reach US$ 7,281.99 million by 2028, registering a CAGR of 8.4% from 2022 to 2028. Reduction in duration of hospital stays and cost of care and increasing incidences of chronic disorders coupled with rising geriatric population are the critical factors attributed to the Europe home infusion therapy market expansion.

Chronic disorders such as cardiovascular, nutritional, and gastrointestinal disorders, rheumatoid arthritis, and neurological disorders affect the overall quality of life. According to the World Health Organization (WHO), over 50% of the global population is estimated to suffer from at least one chronic disease. According to the “Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study,” a large-scale multinational study published in 2021, ~40% of 73,076 adults surveyed from 33 countries in the world were suffering from a functional gastrointestinal disorder (GFID). Age-related gastrointestinal problems are more common in the elderly population, aged 64 and above.

Cardiovascular diseases (CVDs), especially the cases associated with hectic lifestyles, are a significant cause of surging mortality. According to the International Diabetes Federation (IDF), 537 million people worldwide, aged 20–79, had diabetes in 2021, and the number is estimated to rise to 783 million by 2045. Additionally, diabetes was the cause of 6.7 million deaths worldwide in 2021. According to the Neurological Alliance, ~14.7 million neurological cases were registered in 2019, with at least 1 in 6 people suffering from 1 or more neurological conditions.

Aging can cause a consistent loss of physiological integrity, resulting in a reduction in functionality and an increased risk of mortality. The degradation of body function is a key risk factor for contracting the majority of chronic diseases, including diabetes, CVD, and neurological diseases, among elderly patients. According to the Global Ageing Survey 2019, the frequency of a person aged 65 or above is likely to increase from 1 in every 11 inhabitants in 2019 to 1 in every 6 inhabitants by 2025.

The growing baby boomer population suffering from decreased mobility and chronic disorders triggers the demand for home infusion therapies. According to the Department of Economic and Social Affairs updates from December 2021, more than 250 million senior citizens will suffer from moderate to severe disabilities in 2020. Home infusion is a process in which patients receive treatment at home by the administration of drugs or biologicals through needles and catheters. It has proven to be an effective alternative to inpatient care for the treatment of different diseases, both acute and chronic. Additionally, a growing preference for in-home care, especially during the COVID-19 pandemic, has bolstered the demand for home infusion products and services. The utilization of next-generation infusion pumps in homecare settings has also been influenced by improvements in their usability and convenience. Diabetes in the elderly population has pushed forward the need for home infusion pumps for insulin administration. Thus, the rising incidence of chronic conditions, coupled with the growing geriatric population, drives the growth of the home infusion therapy market.  

On the contrary, recalls of infusion pumps and safety concerns associated with home infusion hurdles the growth of Europe home infusion therapy market.

Based on product, the home infusion therapy market is segmented into infusion pumps, intravenous sets, IV cannulas, and needleless connectors. The home infusion therapy market segment is sub segmented into insulin pumps, elastomeric pumps, syringe pumps, and others. The infusion pumps segment held 55.5% market share in 2022, amassing US$ 2,480.82 million. It is projected to garner US$ 4,075.96 million by 2028 to expand at 8.6% CAGR during 2022–2028.  

Based on application, the home infusion therapy market is segmented into enteral nutrition, anti-infective, endocrinology, hydration therapy, chemotherapy, specialty pharmaceuticals, and others. The anti-infective segment held 25.1% market share in 2022, amassing US$ 1,124.13 million. It is projected to garner US$ 1835.63 million by 2028 to expand at 8.5% CAGR during 2022–2028.    

Based on route of administration, the home infusion therapy market is segmented into intramuscular, subcutaneously, and epidural. The intramuscular segment held 75.8% market share in 2022, amassing US$ 3,396.13 million. It is projected to garner US$ 5,570.92 million by 2028 to expand at 8.6% CAGR during 2022–2028.    

Based on country, the Europe home infusion therapy market is segmented into Germany, France, United Kingdom, Italy, Spain the Rest of Europe. Our regional analysis states that Germany captured 29.7% market share in 2022. It was assessed at US$ 1,329.01 million in 2022 and is likely to hit US$ 2,140.18 million by 2028, exhibiting a CAGR of 8.3% during the forecast period.

Key players dominating the Europe home infusion therapy market are B. Braun Melsungen AG; Micrel Medical Devices SA; Baxter International Inc; Nipro Corp; Becton Dickinson and Co; Fresenius Kabi AG; ICU Medical Inc; JMS Co Ltd; Eitan Medical Ltd; and Terumo Corp, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com